今天我们宣布了新的 MONSTAR-SCREEN-3 数据，展示了 Myriad 基于 WGS 的 Precise MRD™ 平台在可切除结直肠癌和胰腺癌术后超敏 #MRD 检测方面的潜力。
👉查看更多：https://bit.ly/4snogy2
#ctDNA #ESMO26 #coloncancer
110 浏览 · 0 赞 · 1 转发 · 0 回复
Utility of ctDNA tumor fraction (TF) as a prognostic biomarker in TALAPRO-3: phase 3 study of talazoparib (TALA) + enzalutamide (ENZA) vs placebo (PBO) + ENZA in patients (pts) with homologous recombination repair (HRR) gene–mutated metasta
https://esmocongress.esmo.orgPlasma ctDNA as standalone or adjunct to tumour tissue for HRR and PI3K/AKT genotyping in mCRPC: PROMPT (NCT04746300)
https://esmocongress.esmo.orgCharacterizing resistance mechanisms and predictors of early progression and long-term response to lorlatinib: Circulating tumor DNA (ctDNA) analyses from the CROWN study
https://esmocongress.esmo.orgClinical utility of reflex liquid comprehensive genomic profiling (LCGP) to complement tumor-informed circulating tumor DNA (ctDNA) monitoring in solid tumors
https://esmocongress.esmo.orgctDNA analysis of the Phase 3 KEYNOTE-B15 trial: neoadjuvant and adjuvant (neoadj-adj) enfortumab vedotin (EV) + pembrolizumab (pembro) for participants (pts) with muscle-invasive bladder cancer (MIBC) who are eligible for cisplatin
https://esmocongress.esmo.orgUltrasensitive monitoring of early ctDNA dynamics during neoadjuvant treatment in early-stage triple-negative breast cancer: Pre-interim results from the B-STRONGER-I study
https://esmocongress.esmo.org来源：Myriad Genetics · x.com